Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa.

Iannone, Michela; Janowska, Agata; Tonini, Giulia; Davini, Giulia; Dini, Valentina

Iannone, Michela; Janowska, Agata; Tonini, Giulia; Davini, Giulia; Dini, Valentina.

Iannone M; Department of Dermatology, University of Pisa, Pisa, Italy. Electronic address: drmichelaiannone@gmail.com.
Janowska A; Department of Dermatology, University of Pisa, Pisa, Italy.
Tonini G; Department of Dermatology, University of Pisa, Pisa, Italy.
Davini G; Department of Dermatology, University of Pisa, Pisa, Italy.
Dini V; Department of Dermatology, University of Pisa, Pisa, Italy.

Clin Dermatol ; 39(4): 701-702, 2021.

Article in English | MEDLINE | ID: covidwho-1233392

Subject(s)

COVID-19; Hidradenitis Suppurativa; Antibodies, Monoclonal, Humanized; COVID-19 Vaccines; Hidradenitis Suppurativa/drug therapy; Humans; RNA, Messenger; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hidradenitis Suppurativa / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Clin Dermatol Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google